Viromed Medical AG has completed its conversion from bearer shares to registered shares following a shareholder resolution approved at the Annual General Meeting on July 29, 2025. The transition became effective after entry into the commercial register on August 8, 2025, representing a significant structural change for the medical technology company specializing in cold plasma applications. This conversion enables increased transparency and direct communication with shareholders while preserving all existing ownership rights, positioning the company for enhanced corporate governance capabilities.
The conversion process involved deregistering all 21,250,000 bearer shares held under ISIN DE000A3MQR65 on January 16, 2026, with shareholders receiving new registered shares under ISIN DE000A40VZN7. Each new share represents €1.00 of share capital, with the global certificate deposited at Clearstream Banking AG in Frankfurt. The final trading day for bearer shares was January 14, 2026, with registered shares commencing exchange trading on January 15, 2026 under the new identifier. Shareholders' proportional stakes in the company remain unchanged throughout this transition, and the transfer of registered shares does not require company approval, ensuring continued trading flexibility for investors.
This structural change represents a strategic administrative shift rather than a financial restructuring, maintaining shareholder value while enhancing the company's ability to communicate directly with its investor base. The registered share structure allows Viromed Medical AG to maintain direct knowledge of its shareholder base, facilitating more targeted communication and engagement. This is particularly important as the company, listed since October 2022, continues developing its medical technology portfolio and pursuing growth through advancing medical cold plasma applications. Additional information about the company is available at https://www.viromed-medical-ag.de.
The transition occurs as Viromed Medical AG focuses on distributing innovative cold plasma technology for medical applications through its subsidiary Viromed Medical GmbH. The company serves a broad customer base in the DACH region and internationally, with this administrative change positioning the organization for future expansion in the healthcare sector while maintaining regulatory compliance and shareholder accessibility. By converting to registered shares, the company gains improved oversight of its ownership structure without altering the fundamental rights or economic interests of existing shareholders, creating a foundation for more effective investor relations and corporate governance as the company advances its medical technology initiatives.
